You are here: / / / 2026

O’Brien et al; “IAP inhibition enhances response to radiotherapy and chemotherapy in preclinical models of rectal cancer”; Radiother Oncol 2026

/in , , ,

O’Brien et al; “IAP inhibition enhances response to radiotherapy and chemotherapy in preclinical models of rectal cancer”; Radiother Oncol 2026

https://doi.org/10.1016/j.radonc.2026.111832

Tiu et al; “IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial”; Nature Communications, 2026

/in , , ,

Tiu et al; “IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial”; Nature Communications, 2026

https://www.nature.com/articles/s41467-026-77552-7

 

 

Fernando et al; “Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy”; Nature Communications, 2026

/in , ,

Fernando et al; “Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy“; Nature Communications, 2026

https://www.nature.com/articles/s41467-026-70133-8